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Abstract
Background In the majority of pediatric patients, the hemo-
lytic–uremic syndrome (HUS) is caused by an infection with
Shiga toxin-producing Escherichia coli (STEC), mostly sero-
type O157. It is important to discriminate between HUS
caused by STEC and complement-mediated HUS (atypical
HUS) due to differences in treatment and outcome. As
STEC and its toxins can only be detected in the patient’s stool
for a short period of time after disease onset, the infectious
agent may go undetected using only fecal diagnostic tests.
Serum antibodies to lipopolysaccharide (LPS) of STEC per-
sist for several weeks and may therefore be of added value in
the diagnosis of STEC.
Methods All patients with clinical STEC-HUS who were
treated at Radboud University Medical Center between 1990
and 2014 were included in this retrospective single-center
study. Clinical and diagnostic microbiological data were col-
lected. Immunoglobulin M (IgM) antibodies against LPS of
STEC serotype O157 were detected by a serological assay
(ELISA).
Results Data from 65 patients weres available for analysis.
Fecal diagnostic testing found evidence of an STEC infection
in 34/63 patients (54 %). Serological evidence of STEC O157
was obtained in an additional 16 patients. This is an added
value of 23 % (p<0.0001) when the serological antibody
assay is used in addition to standard fecal diagnostic tests to
confirm the diagnosis STEC-HUS. This added value becomes
especially apparent when the tests are performed more than
7 days after the initial manifestation of the gastrointestinal
symptoms.
Conclusions The serological anti-O157 LPS assay clearly
makes a positive contribution when used in combination with
standard fecal diagnostic tests to diagnose STEC-HUS and
should be incorporated in clinical practice.
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Diagnostics
Introduction
Hemolytic–uremic syndrome (HUS) is diagnosed when the
characteristics of hemolytic anemia, thrombocytopenia, and
acute renal failure are present [1]. There are different etiolo-
gies leading to HUS, with the Shiga toxin-producing
Escherichia coli (STEC) HUS and complement-mediated
atypical HUS (aHUS) being the most prominent ones. In more
than 90 % of cases, HUS follows a gastrointestinal infection
with STEC. Additionally, over 50 % of STEC-HUS cases are
due to STEC serotype O157, although other serotypes, such as
O26, O103, O145, and O111, are increasingly associated with
HUS as well [2–5].With symptomatic treatment, patients with
STEC-HUS often recover spontaneously, with only a small
number progressing to end-stage renal disease (ESRD) [6].
In contrast, aHUS generally has a poor outcome, with 2–10
% mortality among patients in the acute phase of the disease
and up to 50 % of patients progressing to ESRD [7].
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It is therefore vital to be able distinguish between STEC-
HUS and aHUS, as this has major consequences in terms of
treatment possibilities (for example, the use of the expensive
orphan drug eculizumab, which is currently the standard treat-
ment for aHUS) and outcome [8]. However, it can be chal-
lenging to differentiate clinically between these two entities
due to their similar symptoms. For example, in 6–10 % of
children with STEC-HUS there is no (bloody) diarrhea,
whereas aHUS is preceded by diarrhea in 25 % of the cases
[7, 9]. As HUS is often diagnosed per exclusionum, providing
proof for the presence of STEC forms the basis for differenti-
ation between aHUS and STEC-HUS [2].
In most laboratories, an STEC infection can only be con-
firmed by an examination of fecal material, mostly through
simultanous testing of stool culture, shiga toxins immunoas-
says, and/or polymerase chain reaction PCR assays for the de-
tection of shiga toxin (Stx) genes [10]. With stool cultures, the
presence of an STEC can only be established in a limited num-
ber of patients (approx. 30–69%) with clinical signs and symp-
toms of HUS [4, 11]. The additional use of PCR for detection of
Stx genes increases the odds of finding evidence of an STEC
infection up to 70 % [12, 13]. However, the presence of STEC
in the intestines declines rapidly during the first week of the
illness [10, 14], whereas the average time between the first day
of diarrhea and the development of HUS is 5–13 days [1, 2].
Over two decades ago, Chart et al. described the use of
serological assays to detect antibodies against, among others,
serotype O157 lipopolysaccharide (LPS) as a diagnostic tool
to establish an STEC infection [15–18]. A few studies have
subsequently shown that in patients with clinical signs and
symptoms of HUS, for whom only a limited number of the
stool cultures were positive, the results of serological testing
for STEC were positive in 60–94 % of the patients [4, 11, 19].
The most important explanation for this low number of posi-
tive stool cultures next to the low inoculums of the bacteria is
the small time window when STEC can be detected in the
feces. In contrast, the antibody response, composed of immu-
noglobulin M (IgM), can be detected from 5 days up to
2 months after the onset of the symptoms [20, 21].
Based on these characteristics, a broad application of sero-
logical assays for STEC may be expected. Additionally, in
most of the microbiological studies conducted to date, various
diagnostic techniques have been compared using convention-
al and molecular methods; however, all of these methods de-
pend on the presence of fecal material [13, 22]. Hence, only
limited data have been published on the combined use of fecal
diagnostic testing and the serological antibody assay in pa-
tients with STEC-HUS. A review of the literature and discus-
sion with colleagues suggested to us that interest in the sero-
logical antibody assay for the detection of an STEC infection
has been largely neglected in past years.
In th study reported here, we assessed the added value of
the serological anti-O157 antibody assay in combination with
fecal diagnostic testing in pediatric patients with a clinical
STEC-HUS. We also examined the time window between
the onset of symptoms and testing for STEC using fecal diag-
nostic tests and a serological antibody assay.
Materials and methods
This was a retrospective single-center study which included
all patients who presented with a clinical pattern of STEC-
HUS between 1990 and 2014 to the Pediatric Nephrology
department of the Radboud University Medical Center
Amalia Children’s Hospital. All available clinical and diag-
nostic data were collected. The diagnostic data included the
results of all fecal diagnostic tests [stool cultures, cell cytotox-
icity assays [free fecal Stx test (FStx), used in our center until
June 2011] and PCR analyses for Stx genes (from June 2011
onwards). An enzyme-linked immunosorbent assay (ELISA)
was used as the serological assay for IgM antibodies against
O157 LPS [15].
A clinical pattern of STEC-HUS was defined as signs of a
thrombotic microangiopathy, hemoglobin level below the
lower limit of normal for a specific age, signs indicative of
hemolysis, acute renal failure, thrombocytopenia
of<150×109/l, and (bloody) diarrhea or family members with
diarrhea. Clinical data at presentation and follow-up were col-
lected from the medical records. Hypertension was defined as
repeated blood pressure measurements above the 95th percen-
tile for sex, height, and age [23]. Anuria was defined as a urine
production of <0.1 ml/kg/h for at least 12 h, and oliguria was
defined as a urine output of <0.5 ml/kg/h. Neurological in-
volvement was indicated by apathy, irritability, reduced con-
sciousness, seizures, paralysis, encephalopathy, and coma,
and signs of pancreatic involvement included pancreatitis
and diabetes mellitus. The estimated glomerular filtration rate
(eGFR) was calculated with the Schwartz formula (k-coeffi-
cient = 36.5) [24]. Extent of renal impairment was based on
guidelines from Kidney Disease: Improving Global Outcome
[25]. The onset of disease was defined as the first day of
diarrhea. The time window of the fecal diagnostic tests and
serological antibody assay was defined as the time between
the onset of the symptoms and the collection of feces and/or
serum.
Fecal diagnostic tests
Feces were collected as soon as possible after admission to the
hospital. In cases where feces could not be obtained, a rectal
swab was done. Fecal material was plated on Sorbitol
MacConkey agar containing 1 % sorbitol and on blood agar.
After 24 h of incubation, non-sorbitol fermenting colorless
colonies were tested for agglutination with anti-O157 O-anti-
gen serum. Until 2011, fecal samples were also tested for the
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presence of FStx using cell cytotoxicity assays as previously
described by Karmali et al. [26, 27]. In June 2011, the PCR
assay for the detection of Stx1, Stx2 and virulence genes, E.
coli attaching and effacing gene (eae), and enterohemorrhagic
E. coli hemolysin (hly) in feces replaced the time-consuming
cell cytotoxicity assays as a standard test, in addition to the
stool cultures. Nowadays, when a patient is suspected of HUS
the feces is first tested for the presence of STEC with a PCR
assay. When the assay results are positive, indicating STEC
infection, a stool culture on Sorbitol MacConkey agar plates is
performed. To further determine all strains, we send all iso-
lates to the Dutch National Institute for Public Health and
Environment (RIVM).
Anti-O157 LPS assay
Serum was obtained from all patients and stored at −80 °C
until analysis. Sera were screened for antibodies against the
LPS serotype O157with an ELISA as previously described by
Chart [15]. In brief, the ELISA plates were coated with LPS
from E. coli O157:H7 [List Biological Laboratories Inc.,
Campbell, CA; product code 206, diluted in carbonate buffer
(pH 9.6) to a concentration of 20 ug/ml]. After incubation
overnight at 4 °C, the plates were blocked, and diluted serum
was added to the plate together with predetermined positive
and negative control sera. After addition of the antibody goat
anti-human IgM (Sigma-Aldrich, St. Louis, MO; product code
A0420, diluted 1/500 with phosphate buffered saline with
bovine serum albumin) and substrate (p-nitrophenyl phos-
phate tablets in diethanolaminebuffer), the absorbance was
measured at 405 nm. A positive IgM reaction was defined
by a mean absorbance of >0.800; values of <0.400 were to
be considered negative and values between 0.400 and 0.800
were considered to be dubious and as such taken to be nega-
tive for the purpose of this study.
Statistics
All available clinical variables for each patient were included
in the analysis. Clinical values were expressed as valid per-
centages for categorical variables and as the mean and stan-
dard deviation or median and 25–75 percentile (interquartile
range) for continuous variables, as appropriate. Values for the
serological assays, stool cultures, FStx, or PCR that were in-
conclusive or missing were classified as a negative test result.
The Chi-square test was performed to compare categorical
data and the two-sided t test or Mann–Whitney U test was
used to compare continuous data. To compare positive and
negative test results in relation to the time since onset of dis-
ease, we used binary logistic regression analyses, and
dummies were computed for the categorical variables. P
values of <0.05 were considered to be statistically significant.
Results
Patient characteristics
During the period between 1990 and 2014, 72 children with a
clinical pattern of STEC-HUS were seen in the Radboud
University Medical Center Amalia Children’s Hospital.
Seven patients were excluded because no data on feces and
serology were available for further analysis. The patient char-
acteristics of the 65 children with a clinical pattern of STEC-
HUS are described in Table 1. The majority of patients (79 %)
presented with STEC-HUS before the age of 6 years. All but
two children had diarrhea at presentation (97 %), which was
generally bloody diarrhea (79 %). One patient died in the
acute phase of the disease from a systemic inflammatory re-
sponse syndrome combined with severe STEC-HUS, as prov-
en by positive results for both the fecal diagnostic tests and the
serological assay. Another patient, with proven STEC-HUS
based on fecal and serological tests, did not show any recovery
of renal function and subsequently was placed on hemodialy-
sis before undergoing kidney transplantation.
Serological assays in addition to fecal diagnostic tests
Evidence of an STEC infection was found in 50 patients
(77 %) of the 65 patients with a clinical pattern of STEC-
HUS. Fecal diagnostic tests identified STEC in 34/63 patients
(54 %); in 26 of these 34 patients a STEC strain could be
isolated with culture. Serological evidence of an STEC
O157 infection was found in an additional 16 patients, which
is an added value of 23 % (p<0.0001) when fecal diagnostic
tests are combined with the serological antibody assay to con-
firm the diagnosis of STEC-HUS (Fig. 1; Table 2). Among
those patients with negative stool cultures, the PCR assay was
positive for STEC-HUS in three patients and the cell cytotox-
icity assay (FStx) was positive for STEC-HUS in five patients.
Since implementation of the PCR assay in 2011, Stx genes
have been detected in nine (69 %) of the 13 patients who
presented with HUS. Of these nine STEC infections, seven
were also detected by serological assays. Three additional
patients who tested negative for Stx genes in repeated PCR
assays showed serological evidence of an STEC infection
(Table 2).
Two addtional serotypes, serotypes O26 (n=3) and O5,
were detected in fecal specimens from three and one patient,
respectively,sent to the RIVM for further testing.
Time window between onset of disease and sample
collection
The median time between onset of disease and the col-
lection of feces and serum was 7 (IQR 5–9) and 8 (IQR
5–12) days, respectively. The added value of serology
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became more evident when the fecal and serological
diagnostic tests were run on specimens collected ≥7 days
after the start of the symptoms (Table 3). Within 7 days
after the first manifestation of the symptoms, 14 patients
had negative fecal diagnostic test results; of these, five
(36 %) had positive results on the serological assay,
confirming a STEC infection. However, of the 12 pa-
tients with negative fecal diagnostic test results based
on fecal specimens collected ≥7 days after the start of
the disease, eight (67 %) were found to test positive for
O157 on the serological assay. Hence, when feces and
serology specimens were collected ≥7 days after the
start of the symptoms, the serological antibody assay
had an added value of 33 %, which is significantly
higher than the 14 % added value when the specimens
for testing were collected within 7 days (p= 0.024).
Discussion
Various fecal diagnostic tests are recommended in the litera-
ture to establish an STEC infection as the cause of HUS [10],
including stool cultures, Stx immunoassays, cell cytotoxicity
assays, and PCR for Stx genes. However, limited data are
available published on the benefits of combining fecal diag-
nostic with serodiagnostic testing in patients with STEC-
HUS. The results of our retrospective study show that the
serological anti-O157 antibody assay is of additional value
to the fecal diagnostic tests used in patients with a clinical
STEC-HUS. In our study, use of the standard fecal diagnostic
tests resulted in a STEC infection being detected in half of the
HUS patients; in comparison, evidence of an STEC infection
was detected in 77 % of the 65 patients when serological
testing was used in combination with the standard fecal diag-
nostic tests. The added value of serological testing further
improves when the specimens for testing were collected
≥7 days after the start of the symptoms.
Table 1 Patient characteristics of 65 pediatric patients with a clinical
pattern of hemolytic–uremic syndrome mediated by Shiga toxin-
producing Escherichia coli
Patient parametersa All patients
Male 52 %
Age of onset (years) 2 (1–4)
0–24 months (n= 18) 17 (10–20)
2–6 years (n= 33) 3 (2–4)
≥6 years (n= 14) 11 (9–12)
Symptoms at presentation
Fever 27 %
Diarrhea, total 97 %
Proportion of which was bloody 79 %
Oliguria 29 %
Duration (days) (n = 5) 5 (3–8)
Anuria 59 %
Duration (days) (n= 26) 8 (7–10)
Blood pressure
<95 percentile for age and height 34 %
≥95 percentile for age and height 66 %
Neurological involvement 34 %
Pancreas involvement 3 %
Biochemical evaluation at
presentation (reference range)
Hemoglobin (6.0–9.0 mmol/l) 5.8 (4.8–6.7)
White blood cells (5.0–13.0 × 109/l) 15.3 (10.9–22.3)
Platelet count (210–430 × 109/l) 47 (30–73.5)
Haptoglobin (0.3–1.6 g/l) <0.08 (0.05–0.08)
LDH (<250 U/l) 3720 (2325–5809)
eGFR (>90 ml/min.1.73 m2) 15 (10–24)
Treatment
Dialysis 63 %
Duration of dialysis (days) 10 (7–15)
Erythrocytes transfusion 80 %
≥ transfusions 11 %
Follow up
eGFR at discharge (ml/min.1.73 m2) 55 (43–66)
eGFR< 60 after 5 years follow up
(n = 8) (ml/min.1.73 m2)
4 (6 %)
Received kidney transplantation 1 (2 %)
Diseased 1 (2 %)
Categorical values are presented as an absolute number and/or as a per-
centage of the total. Continuous variables are presented as the median
with the interquartile range (IQR) in parenthesis
LDH, actate dehydrogenase; eGFR, estimated glomerular filtration rate
a The numbers of patients (n) for whom data were available are reported
in parentheses
Fig. 1 Serological anti-O157 antibody assay in addition to the standard
fecal diagnostic tests. Test results from all 65 patients with a clinical
pattern of hemolytic–uremic syndrome mediated by Shiga toxin (Stx)–
producing Escherichia coli (STEC-HUS) for whom serology and fecal
diagnostic tests were performed to confirm a STEC infection. When the
fecal diagnostic test results (stool culture, cell cytotoxicity assay, and/or
PCR) are combined with those of the serological antibody assay, 77 % of
the patients had a confirmed STEC infection (p< 0.0001)
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Our results are in line with those reported by Espié et al. [4]
who studied 900 children with HUS and tested for STEC by
stool culture, PCR assay for Stx genes, and serological assays
for multiple serotypes. In 232 (37 %) children, The presence
of a STEC was confirmed in 232 (37 %) children with a stool
culture and in 37 patients Stx was detected with the PCR
assay. STEC infection was confirmed in 518 (60 %) patients
based on positive serological results, of which 85 % of pa-
tients had serotype O157. The combined use of fecal diagnos-
tics and serology provided evidence of a STEC infection in
590 (66 %) patients. Unfortunately, no further information on
the time window was provided by the authors.
The fecal diagnostic tests (stool culture, cell cytotoxicity
assay, and/or PCR) detected STEC in only half of our patients
with a clinical pattern of STEC-HUS. A few factors may ex-
plain this low number of positive stool cultures, all of which
are linked to the time of presenting in relation to the develop-
ment of the disease. First, the isolation rate of STEC in feces
declines quickly after the first manifestation of the gastroin-
testinal symptoms, and most parents seek medical attention
after the first signs of bloody diarrhea (which is after approx.
3 days). Secondly, there is a low inoculum whereby the odds
of finding a STEC in the feces is also limited during the first
7 days. The third and final factor is that the diarrheal prodrome
has often ceased before the onset of HUS, making detection of
the pathogen or its toxins rather difficult when the fecal
speciment is collected at the time of presenting with a HUS
[1]. Frequent stool collections may be considered one option
to increase the chance to detect a STEC infection.
Furthermore, new and promising techniques have been
Table 2 Proportion of positive
results for the serological
antibody assay for serotype O157
in relation to the fecal diagnostic
test results





Serology data 38 (63 %) 22 (37 %) 60
Missing 5
Fecal diagnostics 63
Missing serology 4 (6 %)
Positive 22 (65 %) 12 (35 %) 34 (54 %)
Negative 15 (60 %) 10 (40 %) 25 (40 %)
Stool culture 63
Missing serology 4 (6 %)
Positive 18 (69 %) 8 (31 %) 26 (41 %)
Negative 19 (58 %) 14 (42 %) 33 (53 %)
FStx, until 2011 33
Missing serology 1 (3 %)
Positive 10 (59 %) 7 (41 %) 17 (52 %)
Negative 9 (60 %) 6 (40 %) 15 (45 %)
PCR, since 2011 13
Missing serology –
Positive 7 (78 %) 2 (22 %) 9 (69 %)
Negative 3 (75 %) 1 (25 %) 4 (31 %)
Test results from all 65 patients with a clinical pattern of Shiga toxin-producingEscherichia coli-hemolytic uremic
syndrome (STEC-HUS) where the serological assay and fecal diagnostic tests were performed to confirm a STEC
infection
Data in table are presented as the absolute number of patients with the percentage of patients a positive or negative
serology result, respectively, given in parentheses. In a few patients, only fecal diagnostic tests were performed;
the missing serology values are presented in the table
FStx, Free fecal shiga toxin test
Table 3 Added value of serology in relation to the time window
between onset of symptoms and collecting material
Diagnostics Proven STEC infection
Total <7 days ≥7 days
Fecal diagnostics 54 % (34/63) 44 % (11/25) 62 % (20/32)
Serology 62 % (38/61) 45 % (9/20) 69 % (25/36)
Combined: fecal
diagnostics & serology
77 % (50/65) 58 % (7/12) 95 % (20/21)
Added value of serology 23 % 14 % 33 %
Collection of diagnostics in the first 6 days after the start of the symptoms
are compared with 7 days or more since onset and the influence on the
detection of Shiga toxin-producing Escherichia coli (STEC) infection is
compared. The added value of serology becomes more evident as of
7 days (p = 0.024)
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developed for the detection of STEC infection since the start
of this retrospective study, as illustrated by the PCR assay for
Stx genes, but also more recently by the molecular approach to
assess the virulence profile and serotyping of STEC strains. In
comparison to the other standard fecal diagnostic tests (e.g.,
stool culture and PCR), molecular testing is generally only per-
formed in reference laboratories, as this approach ismostly used
for epidemiological analysis [10, 28]. The PCR assay for Stx
genes was introduced only a few years ago in our hospital, and
data on this assay were only available for a minority of patients
in our study, although results are promising. Even though these
techniques are more precise in terms of detecting the presence
of STEC, they still require fecal material for testing. Therefore,
in cases without stool production, besides a rectal swab that is
highly recommended, it may still be difficult to detect STEC.
In 15 (23 %) of the 65 patients enrolled in our study, the
results of the serological assay and the fecal diagnostic tests
were negative for a STEC infection. One explanation may be
that the techniques used were not sufficiently sensitive, espe-
cially because the majority of the specimens were tested before
the implementation of the PCR assay. Another possible expla-
nation is the timing of sampling, even though the time between
the onset of symptoms and the collection of fecal specimens in
our cohort is comparable with those of other studies [4, 29]. In
our study, only a serological antibody response against O157
was tested. O157 currently accounts for 30–80 % of STEC-
HUS cases in The Netherlands, and our serological assay could
not detect other important serotypes [4, 30, 31]. Also, the serum
samples may have been collected too early in the disease
course—that is, prior to seroconversion. When these explana-
tions appear to be unlikely, other causes of HUS, such as aHUS,
should be taken into account. However, during follow up, none
of the 15 patients with negative fecal diagnostic and serological
test results presented with a relapse indicative of aHUS or
showed signs of permanent complement dysregulation.
Our results clearly show that a patient with HUS in the
absence of positive fecal diagnostic test results is not equiva-
lent to one with aHUS. Moreover, it may very well be a STEC
infection that is causing the HUS despite the negative fecal
diagnostic test results. The need for regular serological anti-
body assays in patients with HUS becomes even more impor-
tant with the introduction of the new and very expensive com-
plement inhibitor eculizumab as a treatment for aHUS. We
recommend that this assay be performed centrally in special-
ized laboratories per country to guarantee the quality and re-
liability of the assay and thereby ensure its feasibility and
affordability in general clinical use.
The added value of the serological assay in relation to the
time window has not been studied previously. Our results
show that this added value becomes more evident (14 vs.
33 % before and after 7 days, respectively) when the speci-
mens are collected >7 days after the first manifestation of
symptoms. The number of patients in Table 3 is quite small
due to missing data on the time window. In addition, feces
were collected within 7 days in 11 patients, whereas the serum
was collected >7 days after the start of the symptoms, presum-
ably due to negative fecal diagnostic test results. We anticipat-
ed the rise in positive serological assay results after 7 days, as
IgM is detectable approximately 5 days after the onset of the
symptoms [21]. In contrast, the rise in positive fecal diagnostic
test results after 7 days was not expected considering the
awaited rapid decrease of STEC in the feces. The high per-
centage of positive results for the fecal diagnostic tests is part-
ly explained by the inclusion of the cell cytotoxicity tests
(FStx) and PCR assays, both of which are highly sensitive
tests, even after 7 days, as compared to stool culture tech-
niques [20]. However, these techniques all rely on the avail-
ability of fecal material. We recommend testing for the pres-
ence of STEC with fecal diagnostic tests and serological test
concurrently in HUS patients at admission because the time
course of the disease at presentation is often unclear. In the
case of negative fecal diagnostic and serological test results
for specimens tested within 7 days after the start of the symp-
toms, our advice would be to retest for antibodies after ≥7 days
since the onset of disease.
Based on our results, the serological antibody assay seems
to be indispensable to establish a diagnosis of STEC-HUS;
however, the role of serological antibody detection in healthy
controls remains unclear and needs further exploration. In one
study, 22 of the 606 tested healthy controls with high exposure
to cattle carrying STEC had positive serological test results for
O157. However the antibodies found were mainly IgG, which
could be indicative of repeated exposure. Presumably, the IgM
antibody response we test in this study is more indicative of an
acute infection [32]. There is one important limitation of the
serological anti-O157 antibody assay—namely, the possibility
of cross-reaction with subsequent false negative results.
Cross-reaction has been reported for pathogens such as as
Brucella abortus, Yersinia enterocolitica, Vibrio cholera,
Escherichia hermanni, Citrobacter freundii, Citrobacter
sedlakii, and Salmonella [17]. However, these pathogens are
rarely associated with the onset of HUS.
One limitation of our study is its retrospective nature. All
information had to be gathered from medical records, thereby
increasing the odds that the information would be difficult to
interpret or even be missing. Furthermore, serological data
from the antibody assay were available only on serotype
O157; although serotype O157 is still the main serotype asso-
ciated with HUS in the Netherlands, other STEC serotypes
associated with HUS are being increasingly detected.
However, it was not the purpose of this study to investigate
the epidemiology of STEC, rather to evaluate the added value
of the serological assay, which has been perform in our hos-
pital since 1990, in addition to the fecal diagnostic tests to
determine a STEC. STEC serotype O157 is still the cause of
HUS in over 50 % of the cases in the Netherlands. The
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remaining serotypes are more scattered; for example, the sec-
ond most prevalent serotype associated with HUS, serotype
O26, accounts for <20 % of the HUS cases [4, 30, 31]. In our
cohort, four patients had a confirmed STEC infection with a
non-O157 serotype (tested by RIVM)—serotypes O26 and
O5. To increase the detection of the pathogens causing HUS,
we are currently updating the serological antibody assay for
other important serotypes as well.
In conclusion, the serological O157 antibody assay is an
important additional test for the confirmation of STEC, espe-
cially when the fecal diagnostic test results are not sufficient to
establish a STEC infection. Moreover, it is essential to take the
time window into account: when patients present ≥7 days after
the start of the symptoms, the serological antibody assay could
be indispensable to establish a diagnosis of STEC-HUS. We
recommend the implementation of the serological antibody
assay as standard diagnostic method in combination with the
fecal diagnostic tests for all patients who present with a clin-
ical STEC-HUS.
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